TLR6 Activators
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
FSL-1 | 322455-70-9 | sc-396677 | 100 µg | $250.00 | 3 | |
FSL-1 is a potent ligand for TLR6, characterized by its ability to form stable heterodimers with TLR2, which enhances receptor activation. This interaction triggers a cascade of signaling pathways, notably the NF-κB pathway, leading to the production of pro-inflammatory cytokines. The unique structural motifs of FSL-1 facilitate specific binding to the receptor, influencing downstream immune responses and shaping the host's defense mechanisms against pathogens. Its distinct molecular architecture plays a crucial role in modulating immune system dynamics. | ||||||
(R)-FSL-1 | sc-396679 | 100 µg | $370.00 | |||
(R)-FSL-1 serves as a selective agonist for TLR6, engaging in unique molecular interactions that promote receptor dimerization with TLR2. This binding initiates a series of intracellular signaling events, particularly activating the MAPK pathway, which is pivotal in regulating cellular responses. The compound's specific stereochemistry and hydrophobic regions enhance its affinity for the receptor, influencing the kinetics of immune activation and shaping the overall inflammatory response. | ||||||
Polyinosinic acid - polycytidylic acid sodium salt, double-stranded | 42424-50-0 | sc-204854 sc-204854A | 10 mg 100 mg | $139.00 $650.00 | 2 | |
Poly(I:C) is a synthetic double-stranded RNA analog that can activate TLR6 indirectly by binding to TLR3 and triggering downstream signaling pathways, leading to cross-talk with TLR6 signaling and activation. | ||||||
R-848 | 144875-48-9 | sc-203231 sc-203231A sc-203231B sc-203231C | 5 mg 25 mg 100 mg 500 mg | $100.00 $300.00 $500.00 $1528.00 | 12 | |
R848 is a synthetic small molecule that can activate TLR6 indirectly by binding to TLR7 and triggering signaling pathways that cross-talk with TLR6, leading to TLR6 activation. | ||||||
Lipopolysaccharide, E. coli O55:B5 | 93572-42-0 | sc-221855 sc-221855A sc-221855B sc-221855C | 10 mg 25 mg 100 mg 500 mg | $96.00 $166.00 $459.00 $1615.00 | 12 | |
LPS can activate TLR6 indirectly by engaging TLR4 and initiating a cascade of signaling events that result in TLR6 activation through cross-talk between TLR4 and TLR6 signaling pathways. | ||||||
Imiquimod | 99011-02-6 | sc-200385 sc-200385A | 100 mg 500 mg | $66.00 $278.00 | 6 | |
Imiquimod is a synthetic compound that activates TLR6 indirectly by binding to TLR7 and initiating signaling events that cross-talk with TLR6, resulting in TLR6 activation. | ||||||
Pam3Cys-Ser-(Lys)4, Hydrochloride | 112208-00-1 | sc-507471 | 2 mg | $550.00 | ||
Pam3CSK4 is a synthetic lipopeptide that can activate TLR6 directly by binding to TLR1/TLR2/TLR6 heterodimers. It engages TLR6 in a ligand-specific manner, leading to TLR6 activation and downstream signaling. | ||||||
Lipoteichoic acid | 56411-57-5 | sc-507479 | 5 mg | $248.00 | ||
LTA can activate TLR6 directly by binding to TLR2/TLR6 heterodimers. It engages TLR6 in a ligand-specific manner, leading to TLR6 activation and downstream signaling. | ||||||
Zymosan A from Saccharomyces cerevisiae | 58856-93-2 | sc-258367 sc-258367A | 250 mg 1 g | $88.00 $218.00 | 2 | |
Zymosan can activate TLR6 directly by engaging TLR2/TLR6 heterodimers. It engages TLR6 in a ligand-specific manner, leading to TLR6 activation and downstream signaling. | ||||||